- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06027255
Dlouhé COVID Imunitní profilování
Parasympathetic nervous system (PNS) is part of the body's autonomic nervous system(PNS) protects body against inflammation. Study shows that reduced PNS function activity is associated with persistent inflammation.
Preliminary data from the studies shows, that post-COVID-19 POTS patients have reduced parasympathetic (PNS) function. Given that the PNS protects against inflammation, this clinical trial aims to prove that post-COVID-19 POTS is caused by reduced PNS activity, which in turn, contributes to persistent inflammation, orthostatic intolerance, and OI symptoms.
The study will evaluate immune cell activation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity.
Přehled studie
Postavení
Detailní popis
COVID-19 infections can cause a disabling syndrome that persists beyond the 3-month convalescence period. The term post-acute COVID-19 syndrome or Long COVID is coined to describe a cluster of symptoms consisting of fatigue, chest pain, reduced exercise tolerance, tachycardia, and cognitive impairment.
Persistent tachycardia remains one of the most common complaints, reported in 9% of patients at 6 months post-infection. These symptoms overlap with those present in patients with Postural orthostatic tachycardia syndrome (POTS). It is noteworthy that about half of POTS patients also report a history of viral infection prior to the development of these symptoms.
Post-COVID-19 tachycardia syndrome, POTS variant: It present with chronic tachycardia with symptoms of orthostatic intolerance (OI) without any other identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and "brain fog", commonly described in POTS patients are also present in this novel condition.
Elevated levels of inflammatory markers CRP,D-dimer and IL-6 are found in Long COVID patients. Data in POTS, which resembles post-COVID tachycardia syndrome, shows increased cytokines including IL-6, IL-1b, and TNF-a.
Notably, stimulation of the efferent vagus nerve (PNS), has been shown to reduce proinflammatory markers production and systemic inflammation. Hence, decreased PNS function, as reported with acute SARS-CoV-2 infection and in post-COVID-19 POTS patients, may render these patients prone to persistent inflammation. To determine the link between PNS activity and immune activation in post-COVID-19 POTS, the study aims to evaluate immune cell activation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity.
Rationale and Specific Aims:
Preliminary data shows that post-COVID-19 POTS patients have reduced parasympathetic (PNS) function. Given that the PNS protects against inflammation, we hypothesize that post-COVID-19 POTS is caused by reduced PNS activity, which in turn, contributes to persistent inflammation, orthostatic intolerance, and OI symptoms.
Primary Aim: Test the hypothesis that reduced PNS activity is associated with persistent inflammation in patients with post-COVID-19 POTS.
Study Participants:
This is a cross-sectional study conducted, up to 150 patients will be enrolled, 50 POTS without Long-COVID, 50 POTS with Long-COVID and 50 controls with history of COVID-19 infection without sequelae.
Study Procedures
Recruitment: Subjects will be recruited from referrals to the Vanderbilt Autonomic Dysfunction Center (ADC)
Study visit:
Assessments:
- Autonomic symptoms assessment questionnaire (COMPASS-31)
- Quality of life EQ-5D
- PROMIS scale (Functional Activities Questionnaire in Older Adults with Dementia),
- OHQ (Orthostatic Hypotension Questionnaire)
- CBS (Cambridge Brain sciences: Web based cognitive assessment platform, Optional), and neuropsychological tests Blood sample collection: CBC, CMP, C-reactive protein (CRP), D-dimer, Flow cytometry study, PBMC isolation Autonomic function tests: Testing performed at Vanderbilt ADC within 10 years of the study visit will be utilized. Testing will not be repeated solely for the purposes of this study.
Statistical Considerations
Biostatistical Section The primary endpoint serum IL-6. The proposed sample size of 150 (50 POTD, 50 Long COVID POTS patients and 50 controls) provides more than 90% power to detect an effect size of 0.62 for the mean difference in IL-6 between post-COVID-19 POTS (cases) and controls (COVID-19 infected w/o sequelae), with the two-sided type I error = 5%. This calculation is based on the preliminary data of mean difference of IL-6 ≈ 1.82 and the SD ≈ 2.94 in POTS.16 The effect size is defined as the ratio of mean IL-6 difference between cases and controls to standard deviation.
Data analysis plan: Demographic information will be tabulated. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters, as well as percent and frequencies for categorical parameters, will be presented. T-test or Mann-Whitney (as appropriate) will be applied to examine the mean differences between cases and control with respect to the outcomes. The conditional logistic regression model will be applied for the multivariable data analysis. The adjusted p-values and the adjusted 95% confidence intervals (CIs) will be reported.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37027
- Cyndya Shibao
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
The following subject population will be collected
- The subjects with diagnosis of POTS
- The subject who got POTS because of the COVID infection (Long COVID POTS)
- Healthy controls: Subjects who do not have diagnosis of POTS or LONG COVID , after the COVID infection
Popis
Inclusion Criteria:
- Subjects will be 18 years or older, men and women.
- History of confirmed COVID-19 infection (positive contact and symptoms, antigen test or PCR).
- POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncopal symptoms.
- Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncopal symptoms. Symptoms occurred within 2 months after COVID infection and persistent until enrollment in the study.
Exclusion Criteria:
- Individuals with a history of physician diagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack, or who had undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries).
- Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
- Chronic use of steroids, anti-IL6 (omalizumab), anti-TNF-alpha, other immunosuppressants.
- Chronic use of NSAID. Should not enroll if taking without one week prior to blood sampling.
- Treatment with plasmapheresis, IVIG or other immune modulator
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: CASE_CONTROL
- Časové perspektivy: CROSS_SECTIONAL
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Post- COVID 19 POTS patients
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31): In post-COVID-19 POTS (cases). |
Compare IL-6 level , as a marker of inflammation in all the 3 groups:
Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:
Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients |
|
POTS patients
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: patients with diagnosis of POTS |
Compare IL-6 level , as a marker of inflammation in all the 3 groups:
Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:
Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients |
|
Post- COVID 19 POTS patients with Controls
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: Controls are :COVID-19 infected without sequelae |
Compare IL-6 level , as a marker of inflammation in all the 3 groups:
Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:
Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
IL-6 levels
Časové okno: Baseline
|
Parasympathetic (PNS) function, protects against inflammation. To Evaluate level of inflammation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity. The primary endpoint is IL-6 levels |
Baseline
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Orthostatic Symptoms Score
Časové okno: Baseline
|
Standardized Orthostatic Symptoms Score COMPASS-31: Composite Autonomic Symptom Score The COMPASS-31 is a widely-utilized patient questionnaire that provides a quantitative assessment of the severity and distribution of autonomic symptoms . This questionnaire generates a weighted score from 0 to 100, and questions fall into one of six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor function. |
Baseline
|
|
cytokines (IL-17, and IFN-ɣ)
Časové okno: Baseline
|
Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in Post-COVID-19 POTS patients, comparing to controls |
Baseline
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Postinfekční poruchy
- Neurologické projevy
- Nemoci nervového systému
- Patologické procesy
- Chronické onemocnění
- Atributy nemoci
- Infekce dýchacích cest
- Infekce
- RNA virové infekce
- Virová onemocnění
- Nemoci dýchacích cest
- Plicní onemocnění
- Pneumonie, virová
- Zápal plic
- Koronavirové infekce
- Infekce Coronaviridae
- Infekce Nidovirales
- Onemocnění autonomního nervového systému
- Patologické stavy, příznaky a symptomy
- Příznaky a symptomy
- COVID-19
- Postakutní syndrom COVID-19
- Primární dysautonomie
- Ortostatická intolerance
- Syndrom posturální ortostatické tachykardie
Další identifikační čísla studie
- Long COVID
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .